10:08 AM EST - Cardiol Therapeutics Inc. : Announced completion of the Company's Health Canada approved Phase I clinical study of CardiolRx™. CardiolRx is an ultra-pure, extra strength cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC-free (<10 ppm). Cardiol Therapeutics Inc.
shares T.CRDL are trading up $0.06 at $2.62.
